Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

9.29
-0.2000-2.11%
Post-market: 9.290.00000.00%19:30 EDT
Volume:1.29M
Turnover:11.87M
Market Cap:771.81M
PE:-10.72
High:9.37
Open:9.34
Low:8.96
Close:9.49
52wk High:15.10
52wk Low:2.31
Shares:83.08M
Float Shares:70.33M
Volume Ratio:0.77
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8667
EPS(LYR):-0.8930
ROE:-34.18%
ROA:-20.52%
PB:3.37
PE(LYR):-10.40

Loading ...

Immix Biopharma Highlights NXC-201 CAR-T Data in Relapsed/refractory AL Amyloidosis Trial Presentation

Reuters
·
Sep 03

Immix Biopharma Price Target Cut to $19.00/Share from $20.00 by Morgan Stanley

Dow Jones
·
Aug 12

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

MT Newswires Live
·
Aug 11

Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T in Relapsed/refractory AL Amyloidosis

Reuters
·
Aug 11

Immix Biopharma is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)

TIPRANKS
·
Aug 10

Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $25 from $20

THOMSON REUTERS
·
Aug 10

Immix Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Immix Biopharma Q2 FY26 Net Loss Widens to USD 11.56 Million; G&A Expense More than Doubled to USD 7.12 Million

Reuters
·
Aug 08

Immix Biopharma, Inc. Expected to Post a Loss of 18 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Immix Biopharma to Attend Morgan Stanley Global Healthcare Conference, Host Investor Meetings

Reuters
·
Aug 04

Immix Biopharma Initiated at Buy by Needham

Dow Jones
·
Jul 22

Needham Initiates Immix Biopharma at Buy With $21 Price Target

MT Newswires Live
·
Jul 22

Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21

THOMSON REUTERS
·
Jul 22

Immix Biopharma Terminates Richard Graydon Employment

Reuters
·
Jul 20

Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 20

Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis

Reuters
·
Jul 03

Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27

THOMSON REUTERS
·
Jun 18

BofA Initiates Immix Biopharma at Buy With $27 Price Target

MT Newswires Live
·
Jun 18

Immix Biopharma Initiated at Outperform by LifeSci Capital

Dow Jones
·
Jun 18